- Group News
- Fosun Foundation Donates First Batch of HK $10 Million Anti-epidemic Materials to Hong Kong
Fosun Foundation Donates First Batch of HK $10 Million Anti-epidemic Materials to Hong Kong
The severe fifth wave of epidemic in Hong Kong has led the number of confirmed cases surge to record highs for days. In order to support Hong Kong’s fight against the epidemic, Fosun Foundation announced today that it will donate HK$10 million anti-epidemic materials, including COVID-19 rapid antigen test kits and surgical face masks to Hong Kong.
As the fifth wave of epidemic caused by the omicron variant broke out, there has been a huge demand for virus testing among citizens, and the waiting time for Community Testing Centres is long. In addition to surgical face masks, the materials donated by Fosun Foundation also include COVID-19 rapid antigen test kits. The materials will be donated to grassroots people in need, chronically ill patients, etc., through Hong Kong non-profit organizations and family doctor networks to relieve their economic and psychological pressure and respond to the government's call of achieving "early identification, early isolation and early treatment".
Fosun Foundation said, “The fifth wave of epidemic has dealt a heavy blow to Hong Kong and the number of new confirmed cases has continued to rise, which has put enormous pressure on the public healthcare system. Fosun Foundation endeavors to assist and fully support Hong Kong in the fight against the epidemic and tide over difficulties with the whole society by donating relevant anti-epidemic materials, making contributions to anti-epidemic efforts in Hong Kong."
Since the COVID-19 outbreak in early 2020, Fosun Foundation has immediately initiated a global medical supplies deployment plan to provide strong support for China and overseas to fight against the epidemic. In addition to leveraging its global resources advantages to urgently deploy protective materials to assist countries affected by the epidemic, Fosun also partnered with BioNTech, a German biotechnology company, to jointly develop the COVID-19 mRNA vaccine (COMIRNATY®), actively promoting the implementation of vaccine research and development and the launch of the vaccine, thereby providing a strong guarantee for defeating the epidemic. COMIRNATY® (also known as BNT162b2) has been put into use in Hong Kong SAR and Macao SAR in March 2021, and arrived in the Taiwan region on 2 September 2021, which was subsequently put into use, playing an active role in the epidemic prevention and control in Hong Kong SAR, Macao SAR and Taiwan region.
Regarding the fifth wave of epidemic in Hong Kong, Fosun Foundation pays a great tribute to all healthcare professionals and anti-epidemic personnel in Hong Kong for their selfless spirit in fighting the epidemic, and hopes to put an end to the epidemic with the joint efforts of all sectors of society.